Global Sevoflurane Market Size, Share & Forecast, By Product Type, Application & Geography, 2026-2031

The Global Sevoflurane Market was worth USD 1.15 billion in 2025. The estimate covers finished sevoflurane sold for human induction and maintenance of general anesthesia, excluding anesthesia devices, veterinary products and unrelated inhalational agents. It was triangulated using manufacturer revenue, 250 mL-equivalent bottle demand and procedure-based consumption. North America represented the largest regional revenue pool, while hospitals remained the dominant care setting. The confidence interval is USD 1.04-1.27 billion, with uncertainty driven mainly by confidential tender prices and low-flow consumption assumptions.

The market is forecast to reach USD 1.62 billion by 2031, representing a 5.83% CAGR during 2026-2031. Growth will be supported by higher surgical throughput, ageing populations, expansion of ambulatory surgery and substitution away from desflurane. Volume is projected to increase to 15.7 million 250 mL-equivalent bottles, while net ASP rises to approximately USD 102.87. Low-flow anesthesia will restrain milliliters consumed per case, so revenue expansion depends on broader geographic access, improved tender coverage and a gradual shift toward higher-value regulated markets and service-supported contracts.

Incremental profit pools are expected to shift toward generic products, Asia Pacific tenders, ambulatory surgical centers and integrated low-emission delivery services. Generic suppliers can capture volume through lower acquisition prices, while service-supported contracts protect margins through vaporizer support, staff training and inventory management. Asia Pacific is forecast to grow faster than mature markets as surgical access improves. Ambulatory facilities also require smaller, more frequent deliveries and dependable recovery characteristics. Capture systems and consumption analytics create an additional service layer that is less exposed to commodity bottle-price competition.

The most important structural constraint is the adoption of low-flow anesthesia, which reduces sevoflurane consumption per procedure while preserving clinical utility. Modern workstations can maintain target concentrations with substantially lower fresh-gas flow, creating cost and emissions benefits for hospitals but weakening volume growth for manufacturers. Generic tender competition adds further pressure to net realized prices. Companies also face packaging and vaporizer compatibility requirements that can delay switching or trigger field actions. The resulting market favors suppliers with strong regulatory systems, validated filling formats and high account density.

North America led the market with approximately 36% of global revenue in 2025, equivalent to USD 414 million. Leadership reflects high surgical intensity, established reimbursement, advanced anesthesia workstations, broad access to trained professionals and concentrated procurement through health systems and purchasing organizations. Europe ranked second with 28%, while Asia Pacific represented 25% and offered the fastest forecast growth. Mature regions generate higher revenue per procedure, whereas emerging markets provide greater procedure-volume expansion and generic penetration opportunities.

Expansion of access to safe surgery and anesthesia has the greatest long-term effect. WHO estimates that five billion people lack safe, affordable surgical and anesthesia care and that 143 million additional procedures are needed annually. Ageing reinforces this need because the population aged 60 years and above is projected to reach 1.4 billion by 2030. These trends support hospital investment, operating-room capacity and anesthetic demand, although access expansion depends on trained personnel, equipment, financing and reliable medicine supply.

Sustainability requirements will favor sevoflurane relative to desflurane but will also reward lower overall anesthetic consumption. NHS England restricted routine desflurane use from April 2024, and professional guidance indicates a substantially higher climate footprint for desflurane. Hospitals are therefore adopting sevoflurane, intravenous anesthesia, low-flow protocols and waste-gas capture in combination. Suppliers that provide emissions data, efficient vaporizers, capture integration and clinician education can achieve stronger tender positioning, while manufacturers relying only on bottle sales face volume pressure from efficiency measures.